A Phase 3 interventional study of Injectafer and Placebo in Restless Legs Syndrome (RLS), sponsored by American Regent, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-12.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.
Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 20th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2015, is one of 18 in phase 3, and was the 63rd registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:
Noctrix Health, Inc. · Sites in United States
Ages 21+
Rhode Island Hospital · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
HBC Immunology Inc · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 21 · Phase 4 18
First in 1995; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 46 across the 95 interventional studies, 72 across the 12 observational. Of the 83 that completed or were terminated, 35 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
Daiichi Sankyo has 5 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Restless Legs Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT07675109Noctrix Health, Inc.Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) | 2026-12 |
| NCT07061470Hugo W. Moser Research Institute at Kennedy Krieger, Inc.A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 107 studies in Restless Legs Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. The subject's participation in the study will be for approximately 1 year from Day 0.
This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5. All treated subjects will be followed for efficacy and safety for 12 months. Subjects will visit the clinic on Days 0 and 5 for treatment, and then on Days 14, 42, 168, and 365. In between the clinic visits subjects will be contacted remotely on Days 84, 126, 210, 252, 294, and 336. The subject's participation in the study will be for approximately 1 year from Day 0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RLS symptoms affirming diagnosis. The IRLS Diagnostic Criteria must be met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
Drug: Injectafer
IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
Other: Placebo
Also known as: Ferinject®, Iroprem®, Renegy®
Also known as: Normal Saline
International Restless Legs Syndrome (IRLS) Total Score Change From Baseline on Day 42
Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42. Eligible subjects were to have met the following requirements prior to receiving additional treatment: A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.
Time frame: Baseline and Day 42
Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I)
Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
Time frame: Day 42
Clinical Global Impression-Improvement (CGI-S) by Subject
Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
Time frame: Day 42
Restless Legs Syndrome Quality of Life (RLS-QLI) Change From Baseline to Day 42.
The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below: 1. Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100 2. Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100 3. Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100 4. Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100 Note: Resulting scores range between 0-100. Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.
Time frame: Baseline and Day 42
Fatigue Linear Analog Scale Change From Baseline
The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.
Time frame: Baseline and Day 42
Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42
The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis. The "quantity of sleep" dimension is the average number of hours of sleep per night reported by the patient and the "optimal sleep" is a dichotomized version that is "yes" when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).
Time frame: Change from Baseline and Day 42.
Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications
Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.
Time frame: Time from Day 5 to Day 365
| Milestone | Injectafer | Normal Saline |
|---|---|---|
| Started | 105 | 104 |
| Completed | 94 | 91 |
| Not completed | 11 | 13 |
| Withdrew: Withdrawal by subject | 6 | 7 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Subject did not receive study drug | 0 | 1 |
Summary of the actual values of IRLS total score on baseline and Day 42, and the change from baseline to Day 42. Eligible subjects were to have met the following requirements prior to receiving additional treatment: A baseline score ≥ 15 on the International Restless Legs Syndrome (IRLS) Rating Scale. The minimum score is 15 with the maximum of 40. A score of less than 15 is not an indicator of RLS. However, a score of 15 or greater is an indicator of RLS. Further increase indicates more severe disease.
| score on a scale | Injectafer | Normal Saline |
|---|---|---|
| Baseline | 24.1 ± 6.27 | 24.5 ± 6.05 |
| Day 42 | 15.6 ± 8.69 | 18.7 ± 8.94 |
| Change from Baseline to Day 42 | -8.7 ± 8.44 | -5.9 ± 9.07 |
Responder is defined as subjects rated as much or very much improved with the CGI-I on Day 42. Summary of the number (percentage) of CGI-I responder. Per the protocol, the he CGI is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response. The scale requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression (CGI) Performed by Investigator (CGI-I) | 38 | 25 |
Similar to the CGI-I except this is self-reported, 7-item scale for assessment of symptoms after treatment with the rating as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.
| Participants | Injectafer | Normal Saline |
|---|---|---|
| Very much improved | 10 | 7 |
| Much improved | 30 | 19 |
| Minimal change | 31 | 16 |
| No Change | 10 | 12 |
| Minimally worse | 2 | 11 |
| Much worse | 3 | 4 |
| Very much worse | 1 | 1 |
The Restless Legs Syndrome Quality of Life (RLS-QLI) instrument, a self-assessment, 17-item questionnaire with four scales identified through factor analysis: Daily Function, Social Function, Sleep Quality, and Emotional Well-Being, developed to facilitate clinical research on RLS. Scoring Instructions below: 1. Social Function = Sum (Items 1, 2, 3, 4), subtract 4, divide by 16, multiply by 100 2. Daily Function = Sum (Items 5, 6, 13,14, 15, 16), subtract 6, divide by 24, multiply by 100 3. Sleep Quality = Sum (Item 7, 8, 9, 17), subtract 4, divide by 18, multiply by 100 4. Emotional Well-being = Sum (Items 10, 11, 12), subtract 3, divide by 12, multiply by 100 Note: Resulting scores range between 0-100. Higher scores on the RLS-QLI indicate a lower quality of life. Lower scores indicate a higher quality of life.
| units on a scale | Injectafer | Normal Saline |
|---|---|---|
| Baseline | 55.6 ± 15.0 | 54.3 ± 13.08 |
| Day 42 | 65.2 ± 15.49 | 62.8 ± 14.90 |
| Change from Baseline to Day 42 | 9.0 ± 12.48 | 8.7 ± 14.61 |
The Fatigue Linear Analog Scale is a self-assessment scale in which a 100 mm line is used to measure the severity of fatigue and its effect on a person's activities and lifestyle. The scale severity measure ranges from No Fatigue to Worst Possible Fatigue.
| units on a scale | Injectafer | Normal Saline |
|---|---|---|
| Baseline | 49.78 ± 26.32 | 57.34 ± 23.61 |
| Day 42 | 38.90 ± 26.25 | 42.57 ± 27.13 |
| Change from Baseline to Day 42 | -9.98 ± 27.55 | -16.50 ± 28.32 |
The MOS-Sleep scale, is a 12-item standardized, validated questionnaire for assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache which has been demonstrated to be sensitive to RLS treatment effects. This questionnaire provides information about sleep quality. Individual questions can be used for analysis but summary or index scores of a group of questions, is more commonly used in analysis. The "quantity of sleep" dimension is the average number of hours of sleep per night reported by the patient and the "optimal sleep" is a dichotomized version that is "yes" when the number of hours of sleep is 7 or 8. The scores of the dimensions and of the sleep problem index were converted to a 0 to 100 scale, with higher scores reflecting more of the attribute implied by the name (e.g. greater sleep disturbance, greater adequacy of sleep).
| score on a scale | Injectafer | Normal Saline |
|---|---|---|
| Medical Outcomes Study(MOS) Sleep Scale Change From Baseline to Day 42 | -13.086 ± 1.829 | -9.015 ± 1.902 |
Subjects could start tapering off pre-enrollment prescribed RLS medications after Day 5 until Day 365.
| days | Injectafer | Normal Saline |
|---|---|---|
| Time Off Pre-Enrollment Prescribed Restless Legs Syndrome (RLS) Medications | 34 (34 to 164) | 61 (61 to 183) |
Collected over 2 years, I month. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Injectafer | 1/107 (0.9%) | 6/107 (5.6%) | 72/107 (67.3%) |
| Normal Saline | 0/101 (0%) | 4/101 (4%) | 19/101 (18.8%) |
| Event | Injectafer | Normal Saline |
|---|---|---|
| Haemorrhagic strokeNervous system disorders | 0/107 | 1/101 |
| CellulitisInfections and infestations | 0/107 | 1/101 |
| Forearm fractureInjury, poisoning and procedural complications | 0/107 | 1/101 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/107 | 1/101 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/107 | 0/101 |
| GoutMetabolism and nutrition disorders | 1/107 | 0/101 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/107 | 0/101 |
| Cerebral haemorrhageNervous system disorders | 1/107 | 0/101 |
| SyncopeNervous system disorders | 1/107 | 0/101 |
| DiarrhoeaGastrointestinal disorders | 1/107 | 0/101 |
| Event | Injectafer | Normal Saline |
|---|---|---|
| NauseaGastrointestinal disorders | 10/107 | 1/101 |
| HypophosphataemiaMetabolism and nutrition disorders | 8/107 | 1/101 |
| DizzinessNervous system disorders | 8/107 | 1/101 |
| HeadacheNervous system disorders | 5/107 | 6/101 |
| Feeling hotGeneral disorders | 6/107 | 0/101 |
| FlushingVascular disorders | 6/107 | 0/101 |
| Blood pressure increasedInvestigations | 5/107 | 1/101 |
| Alanine aminotransferase increasedInvestigations | 5/107 | 1/101 |
| Blood pressure systolic increasedInvestigations | 5/107 | 1/101 |
| Hot flushVascular disorders | 5/107 | 1/101 |
One subject did not receive study drug and was excluded from the Safety and Full Analysis Set Populations.
| Age, Continuous(Years) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Mean | 58.3 ± 12.31 | 56.9 ± 13.73 | 57.6 ± 13.01 |
| Sex: Female, Male(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Female | 69 | 71 | 140 |
| Male | 36 | 32 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 9 | 21 |
| Not Hispanic or Latino | 93 | 94 | 187 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 2 | 4 | 6 |
| White | 101 | 99 | 200 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| United States | 42 | 34 | 76 |
| Europe | 65 | 67 | 132 |
| Height(cm) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Mean | 167.6 ± 9.4 | 167 ± 9.4 | 167.3 ± 9.4 |
| Weight(kg) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| Mean | 82.8 ± 21.4 | 79.1 ± 20.8 | 81 ± 21.1 |
| Iron intolerance(Participants) | Injectafer | Normal Saline | Total |
|---|---|---|---|
| No | 104 | 103 | 207 |
| Yes | 1 | 0 | 1 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2015 to primary completion in Jan 2018, 36 months.
Results were first posted in Oct 2021, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose